substantial risk of recurrence, metastasis, and death, with a. 5-year overall survival ... ment of micrometastasis; and facilitates in vivo assessment of. Association ..... and five (9%) had contralateral breast cancer occurrence. The. 5-year DFS and
Approximately 8% to. 30% of newly diagnosed breast cancers are at an advanced ..... might bring a better prognosis in luminal B subtype than was observed in ...
Dec 8, 2014 - multicentric tumors, or those with a contraindication to radi- ation therapy ..... involvement of the retroareolar tissue were proposed as inclu-.
Apr 24, 2014 - licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution ... miR-146b, miR-155, miR-181a, miR-200c, and miR-205 were.
Mar 27, 2012 - ulation tests without specific symptoms to massive thomboem- bolism and disseminated intravascular coagulation. The underly- ing pathophysiology is ..... (EGOG), the premenopausal women receiving chemotherapy and tamoxifen had signific
Each array block contained both tumor and control tissue sam- ples. Multiple ... TMA H&E-stained sections were reviewed under light micros- copy to confirm the .... ILC (n = 1). Medullary (n = 1) ..... Stephenson GD, Rose DP. Breast cancer ... Reneha
Mar 7, 2014 - Rui Deng, Shi-min Wang, Tao Yin, Ting-hong Ye, Guo-bo Shen, Ling Li, Jing-yi Zhao1, Ya-xiong Sang, Xiao-gang Duan,. Yu-quan Wei.
Oct 19, 2013 - Tubular carcinoma (TC) of the breast is an uncommon his- tological subtype of invasive breast cancer that accounts for approximately 1% to 5% ...
Mar 6, 2013 - Anaye A, Perrenoud G, Rognin N, Arditi M, Mercier L, Frinking P, et al. Differentiation of focal liver lesions: usefulness of parametric imaging.
Size of biopsy specimen (cm) 3.98 (2.2-6.8) 4.12 (2.5-7.1). 0.44. Tumor size (cm). 2.89 Â± 0.6. 2.98 Â± 0.7. 0.31. Time to surgery (days). 20.3 Â± 4.1. 18.1 Â± 3.8. 0.08.
Mar 6, 2014 - that the findings of this study add a valuable contribution to the investigation of breast cancer treatment based on photo- dynamic therapy.
Impact of Triple-Negative Breast Cancer Phenotype on Prognosis in Patients with Stage I Breast ..... negative), luminal B (HR- and HER2/neu-positive), HER2+.
Aug 26, 2014 - ity of harboring the BRCA1/2 gene mutation can be reason- ably suspected .... Emirates, South Korea, Saudi Arabia, and Singapore. In recent ...
Jul 11, 2014 - ear transducer (Voluson 730 Expert; GE Healthcare, Chalfont. St. Giles .... PB alone is usually >5%, which, according to current guide- lines, is ...
Oct 23, 2012 - Surgical treatment for breast cancer includes breast con- servation .... sealing system but not the cost of treatment. ..... Prevention of lymphocele.
May 18, 2014 - Ramakrishnan N, Clay ME, Friedman LR, Antunez AR, Oleinick NL. Post-treatment interactions of photodynamic and radiation-induced.
Jun 21, 2012 - Abstract. Breast cancer is the second most fatal cancer in American women. To increase the life ex- pectancy of patients with breast cancer new diagnostic and prognostic biomarkers and drug targets must be identified. A change in the g
Persistent Pain after Breast Cancer Treatment: A Questionnaire-Based Study ... women (38.3%) reported experiencing pain at the surgical site. Body mass index ...
Jan 23, 2014 - 71(46.41). 24 (34.78). Time between the. Recruitment and diagnosis of En- dometrial Cancer. 0.20. 6 months ~ â¦1.5 year. 42(27.45). 28 (40.58).
Jun 23, 2016 - drive the differentiation of triple negative breast cancers. 'Resisting cell death' ... hallmarks of cancer, i.e., 'sustaining proliferative signaling' ...
SECRETION LEADING TO GRANULOMATOUS. MASTITIS. The etiology of IGM remains unclear. The postulated causes have included autoimmune diseases such as granulomatous thyroiditis, granulomatous prostatitis, granulomatous orchitis, immune response to local
Jan 11, 2013 - Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India. REVIEW ARTICLE. J Breast Cancer 2013 March; 16(1): 1-11 ..... imaging methods were used to track their movement along the lymphatic c
ed with HER2-negative luminal B, HER2-positive luminal B, and. HER2 type and ... Data regarding patient age at initial diagnosis, tumor size, histological type ...
Aug 14, 2018 - A nipple-sparing mastectomy is performed to improve a patient's quality of life ... tuitary adenoma surgery visited the outpatient clinic owing to.
DOI: 10.26717/BJSTR.2017.01.000155 Arif Adnan Shaukat. Biomed J Sci & Tech Res
Chemotherapy Safety Standards in the Developing World: is G CSF the Only Option? 1
Arif Adnan Shaukat and 2Touqeer Ahmed Siddiqui
Prince Sultan Military Medical City Riyadh, Saudi Arabia
Associate Consultant Medical Oncology, Saudi Arabia
Received: June 23, 2017; Published: June 28, 2017
*Corresponding author: Arif Adnan Shaukat, Prince Sultan Military Medical City Riyadh, KSA, Saudi Arabia, Email:
Editorial The developing world poses a new set of challenges for the ever more demanding field of oncology. Not only that one has to cope with the concept of new treatments, there are different patient expectations and difficulties with compromised and limited services in remote areas. Issues such as language barriers, paucity of trained staff and lack of health educators are common and need to be kept in check before confirming any treatment options. In this environment there are tough challenges like suitability for appropriate chemo regimen particularly in the palliative setting, safety of treatment delivery and monitoring. Furthermore there is little if any expertise available in remote areas that can cope with different treatment related toxicities. Combined with reluctance of people to travel considerable distances to reach medical facilities, problems are often overlooked and present at a stage too late for salvage. In this environment will it be safe to rely on measures such as G CSF only and a bigger question will this be enough? In accordance with the available evidence, hematological toxicity from chemotherapy, neutropenic complications in particular are the most fearsome. This is counted to be the most common cause for serious events in chemotherapy related treatments as well as commonest reasons for hospital admissions as well as delay in subsequent chemotherapy cycles that can prove to be detrimental in patients overall outcome .
In line with the proposed guidelines NCCN as well as EORTC guidance updated in 2011, there are recommendations for prophylactic as well as therapeutic usage of G CSF. This is based on percentage risk of FN (febrile neutropenia) associated with a particular regimen. This has been classified as High risk based on the 20% or more incidence of FN with a known chemo regimen or Intermediate i.e. between 10-20% risks of FN. In addition there are identifiable patient related factors such as age and co morbidities that have also been suggested as important in decision algorithms for the use of G CSF [2-5]. Risk assessment dictates the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization Low-risk patients
are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] <500 cells/microL) for ≤7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction. Most patients receiving chemotherapy for solid tumors are considered to be low-risk for complications requiring hospitalization or prolonging hospitalization.
High-risk patients are defines as those who are expected to be neutropenic (ANC <500 cells/microL) for >7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia. Along with Other criteria that confer a high-risk Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC ≤100 cells/microL) for >7 days based on experience that such patients are the most likely to have life-threatening complications [2,3]. However, formal studies to clearly differentiate between patients with an ANC <500 cells/microL and ≤100 cells/microL are lacking An alternative to using the clinical criteria described above is to use the Multinational Association for Supportive Care in Cancer (MASCC) risk index, which is a validated tool for measuring the risk for neutropenic fever-related medical complications [5,6]. This is all well and good as far as prevention of hospital admissions and maintaining dose intensity is concerned, however, studies looking into the usefulness of the use of G CSF are clear on the fact that serious morbidity or deaths are not preventable by G CSF use. Under these circumstances, what factors will benefit the patients most of whom will be offered chemotherapy as palliative option for modest extension in life. It is difficult to ignore the fact that toxicities commonly related to chemotherapy leading to compromise in quality of life such as tiredness, nausea, poor taste, peripheral neuropathy etc will not benefit from G CSF intervention. Incidence of these common problems are far greater fear factors for the patients and a leading cause for declining or early discontinuation of chemotherapy. This begs the question, how do we improve on this particular predicament?
Cite this article: Arif A S,Touqeer A S . Chemotherapy Safety Standards in the Developing World: is G CSF the Only Option?. Biomed J Sci & Tech Res. 1(1)-2017. BJSTR.MS.ID.000155. DOI: 10.26717/BJSTR.2017.01.000155
Arif Adnan Shaukat. Biomed J Sci & Tech Res The answer is complex in its simplicity. Stating the obvious, education of the patients and monitoring of the effects with early intervention. This is a simple statement; however, its application to the practices in KSA will not be as simple. Recently, we undertook the task of auditing our prescribing practices for G CSF in patients attending our chemotherapy day unit as an outpatient. Purpose of this audit was to compare our prescribing practices in accordance with the published guidelines. Our finding were interesting and indicative of the concerns as outlined in this article. We found that more patients with intermediate to low risk of neutropenia, as defined by the NCCN and ESMO guidelines, irrespective of the co morbidities, age and factors such as use of polypharmacy as an indicator of their general health were prescribed G CSF. Duration of treatment varied between 3 to 7 days. This was dependent on the proximity of patient’s residence to our center where a patient requiring longer travel are more likely to be prescribed longer duration of treatment.
Another factor identified that correlated well with over generous prescribing was the understanding and experience of the prescriber. Due to lack of available guidelines the prescribers, usually middle grade clinicians, would do so as a result of their personal views and perceptions which mainly revolved around medico legal issues and self-protectionism. Another interesting revelation that emerged through the audit is that the dispensing of the G CSF injections was largely incorrect. Patients or the relatives who received the dispensed medications were provided these in plastic bags and not cool bags, in line with the product dispensing guidelines, where the correct temperature could be modulated. Otherwise in the usual 48-50 degrees Celsius summer temperatures viability of the medication cannot be guaranteed. It is perhaps due to this reason that despite generous prophylactic use of G CSF even in intermediate risk categories there was a slightly higher neutropenia rate.
As a model, Safer Chemotherapy guidelines as proposed by American Society of Clinical Oncology in association with Oncology
Volume 1- Issue 1: 2017
Nursing society and National Health Service (NHS) National Chemotherapy Advisory Group (NCAG), have made specific recommendations . This includes a team structure that will cater for all aspects of patients care at all levels of their treatment journey. This team should comprise of consultants, chemo nurses who are well versed in the management of cancer treatments, 24 hours accessible phone service manned by staff well experienced in chemotherapy treatments, primary care physicians who can be advised and can help manage patients concerns and last but not the least an acute oncology set up that can deal with complications arising as a consequence of treatments. Suffice to say that only through these measures as well as setting of National standards and monitoring of outcomes from treatments offered can the safety goals be achieved. Question remains; how are we to achieve these targets in the developing systems?
1. Guidance for Management of Febrile Neutropenia Michael Gabay, Maria Tanzy Pharmacy Practice News Dec 2009.
2. Michael N Neuss, Martha Polovich, Kristen McNiff, Peg Esper, Terry R Gilmore, et al. (2013) Updated American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. Oncology Nursing Forum 40(3).
3. J Crawford, C Caserta F Roila (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications On behalf of the ESMO Guidelines Working Group. Annals of Oncology 21 (Supplement 5): v248–v251. 4. Thomas J Smith, Kari Bohlke, Gary H Lyman, Kenneth R Carson, Jeffrey Crawford, et al. (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28): 3199-3212.
5. Klastersky J, Paesmans M, Rubenstein EB (200) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J ClinOncol 18:3038. 6.
National Comprehensive Cancer Network (2013) (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancerrelated infections.
Assets of Publishing with us • Global archiving of articles
• Immediate, unrestricted online access • Rigorous Peer Review Process • Authors Retain Copyrights • Unique DOI for all articles http://biomedres.us/